Investor Presentaiton
Dedicated facility for NME research:
Zydus Research Centre
Areas of focus:
Dyslipidemia, Diabetes,
Obesity, Inflammation
Project
Target Indication
Drug Lead Pre-
discover optimiza | clinical
IND
Phase Phase | Phase I
NDA
y
tion develop
ment
Facility for target
identification to pre-
clinical research/early
ZYH1
PPAR alpha Dyslipidemia
: gamma
ZYH2
|PPAR alpha: Diabetes
gamma
ZYH7
PPAR alpha Dyslipidemia
clinical development
ZYM
Multi-modal
Pain
Signed a new drug
discovery and
ZYO1
CB-1
Obesity
aatagonist
development pact with Eli
Lilly and Co., focused on
cardiovascular research
Joint research with Karo
Bio, Sweden for non-
steroidal glucocorticoids
Initiated NDDS product
development based on
Nanotechnology
ZYT1
TR-beta Dyslipidemia
agonist
ZYOG1
Oral GLP-1 Diabetes
agonist
Obesity
ZYD1
GLP-1
Diabetes
agonist
Obesity
ZYGL241
Oral GLP-1 Diabetes
agonist Obesity
ZYGK1
Glucokinase Diabetes
activator
ZYG19
GPR-119
Diabetes
agonist
ZYPH0907 PTH agonist Osteoporosis
19View entire presentation